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ABSTRACT
Bone metastasis is a lethal and morbid late stage of breast cancer that is currently 
treatment resistant. More effective mouse models and treatment are necessary. High 
bone-metastatic variants of human breast cancer cells were selected in nude mice by 
cardiac injection. After cardiac injection of a high bone-metastatic variant of breast 
cancer, all untreated mice had bone metastases compared to only 20% with parental 
cells. Treatment with tumor-targeting Salmonella typhimurium A1-R completely 
prevented the appearance of bone metastasis of the high metastatic variant in nude 
mice (P < 0.001). After injection of the highly bone-metastatic breast cancer variant 
to the tibia of nude mice, S. typhimurium A1-R treatment significantly reduced tumor 
growth in the bone (P < 0.001). These data indicated that S. typhimurium A1-R is 
useful to prevent and inhibit breast cancer bone metastasis and should be of future 
clinical use for breast cancer in the adjuvant setting. 
INTRODUCTION
Bone metastasis is found in more than 80% of 
patients in advanced stages of breast cancer [1] and is 
highly treatment resistant and results in extreme pain 
and high mortality. More effective mouse models and 
treatment are necessary. 
S. typhimurium, which is a facultative anaerobe, was 
previously attenuated with purine and other auxotrophic 
mutations, for cancer therapy [2]. In a Phase I clinical 
trial on patients with metastatic melanoma and renal cell 
carcinoma, the S. typhimurium strain tested (VNP20009) 
was attenuated by lipid A-modified (msbB) and purine 
auxotrophic (purI) mutations. VNP20009 was safely 
administered to patients but colonized the patients’ tumors 
to a limited extent, perhaps because it was over-attenuated 
[3]. 
Another strain of S. typhimurium, A1-R, has 
been developed by our laboratory which has increased 
antitumor efficacy. S. typhimurium A1-R is auxotrophic 
for Leu-Arg which prevents it from mounting a continuous 
infection in normal tissues, but does not inhibit tumor 
targeting and virulence. S. typhimurium A1-R has no other 
attenuating mutations as does VNP20009 and, therefore, 
may have higher tumor virulence. 
The ability to grow in viable tumor tissue may 
account, in part, for the unique antitumor efficacy of S. 
typhimurium strains [4]. 
S. typhimurium A1-R was able to eradicate primary 
and metastatic tumors in monotherapy in nude mouse 
models of prostate, breast, and pancreatic cancer, as well 
as sarcoma and glioma [4-10]. Tumors with a high degree 
of vascularity were more sensitive to S. typhimurium A1-
R, and vascular destruction appears to play a role in S. 
typhimurium A1-R antitumor efficacy [11,12]. Tumor 
vessel destruction and tumor-growth inhibition was 
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enhanced by primer dosing of S. typhimurium A1-R in 
immunocompetent transgenic mice expressing the nestin-
driven green fluorescent protein (ND-GFP), which is 
selectively expressed in nascent blood vessels [13].
S. typhimurium A1-R targeted the Lewis lung 
carcinoma (LLC) growing subcutaneously in nude mice 
[14] whereby the bacterially-infected cancer cells greatly 
expanded and burst and lost viability [15].
We have also shown that S. typhimurium A1-R can 
target chemo-resistant pancreatic cancer stem-like cells 
[16] and pancreatic cancer patient-derived orthotopic 
xenograft (PDOX) models [17-19]. 
In the present study, we demonstrate that S. 
typhimurium A1-R can prevent human breast cancer 
bone metastasis using a metastatic variant in nude mouse 
models.
RESULTS AND DISCUSSION
Efficacy of S. typhimurium A1-R on MDA-MB-435 
cells in vitro
To determine the efficacy on breast cancer cells, 
MDA-MB-435 cells, were treated with S. typhimurium 
A1-R for 1 h. Fluorescence imaging demonstrated that S. 
typhimurium A1-R expressing GFP selectively invaded 
and replicated intracellularly in the MDA-MB-435 cells 
expressing RFP (Fig. 1a). Clonogenic assays demonstrated 
that S. typhimurium A1-R inhibited proliferation of MDA-
MB-435-GFP cells in a dose-dependent manner (Fig. 1). 
Figure 1: Efficacy of S. typhimurium A1-R in vitro on 
breast cancer cells. Clonogenic assays were performed as 
previously described [26]. MDA-MB-435-RFP or MDA-MB-
435-GFP cells were planted in 35 mm dishes. MDA-MB-435-
RFP cells were observed 24 h after the S. typhimurium A1-R 
treatment with the FV1000 confocal microscope. MDA-MB-
435-GFP colonies were fixed with methanol and stained with 
1% crystal violet 8 days after S. typhimurium A1-R treatment. 
ImageJ (National Institutes of Health, Bethesda, Maryland, 
USA) was used to quantify the colonies of the cells. a) S. 
typhimurium A1-R expressing GFP invaded (arrow 1) and 
replicated intracellularly (arrow 2) in MDA-MB-435-RFP cells. 
The infected cells fragmented (arrow 3). b) S. typhimurium 
A1-R inhibited proliferation of MDA-MB-435-GFP cells in a 
dose-dependent manner. c) MDA-MB-435-GFP colony number 
after A1-R treatment. *p < 0.05, **p < 0.01 compared with the 
control group.
Figure 2: Distribution of S. typhimurium A1-R in bone 
marrow and other organs.One, 2, 3, 7, 14, and 28 days after 
injection of S. typhimurium A1-R, the non-tumor-bearing 
mice were sacrificed and blood, spleen, and bone marrow 
were harvested and irrigated with PBS. PBS containing S. 
typhimurium A1-R from each tissue was cultured on LB agar. a) 
Collection of bone marrow. After the resection of the femur, two 
holes were made in both ends. After irrigation, a portion of the 
PBS was cultured on LB agar for 24 hours. b) Colony formation 
of GFP-expressing S. typhimurium A1-R obtained from blood, 
spleen, and bone marrow which were harvested 14 days after S. 
typhimurium A1-R treatment. S. typhimurium A1-R fluorescent 
colonies were imaged with the OV100 Small Animal Imaging 
System.
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S. typhimurium A1-R survives in bone marrow
After injection of S. typhimurium A1-R (5×107 
CFU, i.v.) to non-tumor-bearing nude mice, blood, spleen, 
and bone marrow were cultured on Luria-Bertani (LB) 
agar (Fig. 2a). The presence of S. typhimurium A1-R 
was confirmed by GFP-expressing colony formation 24 
hours after culture (Fig. 2b). These results showed that S. 
typhimurium A1-R survived for 2 weeks in bone marrow, 
compared to only 3 days in spleen. Blood had no colony 
formation on LB agar. 
In vivo selection of highly metastatic breast cancer 
cells
MDA-MB-435-GFP cells formed experimental 
bone metastases after injection in the left cardiac ventricle 
injection of nude mice (Fig. 3a). Bone metastases become 
detectable by fluorescence six weeks after inoculation 
of parental MDA-MB-435-GFP cells (2×105), and 
appeared in 20% of inoculated mice. High metastatic 
variants obtained after 1−4 cycles of in vivo selection 
were progressively termed MDA-MB-435-GFP-BM1, 
-BM2, -BM3, and -BM4. After 4 cycles of selection, 
the highly metastatic cell line MDA-MB-435-GFP-BM4 
was obtained (Fig. 3b). MDA-MB-435-GFP-BM4 cells 
generate detectable bone metastases 3-4 weeks after 
inoculation, in 100% of the mice inoculated (Fig. 3c).
Efficacy of S. typhimurium A1-R therapy on 
experimental bone metastasis
Nude mice (n=10) were injected in the left ventricle 
with MDA-MB-435-GFP-BM4 cells (2×105). One 
week after cardiac injection, mice (n=5) were treated 
3 times with weekly i.v. injection of S. typhimurium 
A1-R (Fig. 4a). Four weeks after cardiac injection of 
MDA-MB-435-GFP-BM4 cells, fluorescence imaging 
showed experimental metastatic bone metastasis in all 
of the untreated control mice (Fig. 4b). In contrast, no S. 
typhimurium A1-R-treated mouse had bone metastasis 
during the 12-week observation period (P = 0.009) (Fig. 
4c).
Efficacy of S. typmimurium A1-R on breast cancer 
cell growth in the tibia 
MDA-MB-435-GFP-BM4 cells (5×105) were 
injected into the intramedullary cavity of the tibia in 
nude mice (n=12) (Fig. 5a). Two weeks after intratibial 
injection of cancer cells, six mice were treated three 
times with weekly i.v. S. typhimurium A1-R (Fig. 5b). 
Figure 3: In vivo selection of highly brain-metastatic cancer cells. a) Schematic representation of the in vivo cyclic selection 
process for high bone-metastatic variants. MDA-MB-435-GFP cells were inoculated into the left cardiac ventricle of nude mice. Six weeks 
after injection, experimental bone metastases were detected by fluorescence imaging. Cancer cells were isolated from bone metastases and 
re-inoculated in the left ventricle after expansion in culture. Cells isolated from the second round of metastases were expanded in culture 
and re-inoculated in the left ventricle for a total of 4 cycles. b) Kaplan-Meier curves for metastasis-free survival of mice inoculated in the 
left ventricle with MDA-MB-435-GFP-BM1-4 cells compared with the parental MDA-MB-435-GFP cells (BM0) (*p < 0.05). c) Time-
course imaging of breast cancer bone metastasis. MDA-MB-435-GFP-BM4 cells were inoculated into the left cardiac ventricle of nude 
mice. Fluorescence imaging visualized the progression of metastases in multiple bones including skull, femur, and vertebra. 
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Figure 4: Efficacy of S. typhimurium A1-R on experimental 
bone metastasis after cardiac injection. a) Study protocol. 
MDA-MB-435-GFP-BM4 cells were injected into the left 
ventricle in nude mice (n=10). On day 7, 14, and 21, S. 
typhimurium A1-R (5×107 CFU/mouse, n) were administered to 
mice (n=5). Fluorescence imaging was performed every week. 
b) Metastasis-free survival of mice treated with S. typhimurium 
A1-R or untreated controls was determined using the Kaplan-
Meier method with log-rank test. c) Time-course fluorescence 
imaging of breast cancer bone metastasis with or without 
treatment of S. typhimurium A1-R. MDA-MB-435-GFP-BM4 
cells were inoculated in the left cardiac ventricle of nude mice. 
Fluorescence imaging visualized the progression of metastases 
in multiple bones including skull, femur, and vertebrae in control 
mice. In contrast, there was no fluorescence in the mice treated 
with S. typhimurium A1-R. 
Figure 5: a) Experimental schema of approximately 
5 mm midline skin incision was made to expose the 
tibial tuberosity. MDA-MB-435-BM4 cells (2×105) in 5 µl 
Matrigel (BD Bioscience, San Jose, CA) were injected in the 
intramedullary cavity of the tibia. b) Study protocol. Two weeks 
after intratibial injection, fluorescence imaging was performed 
to confirm the growing GFP-expressing tumor using the iBOX 
Scientia Small Animal Imaging System (UVP LLC, Upland, 
CA, USA). Mice (n=5) (treatment group) were administered 
S. typhimurium A1-R (5×107 CFU, i.v.) once a week for 3 
weeks. The remaining mice (untreated control group, n=5) were 
administered the same volume of PBS. Fluorescence imaging 
was performed on treated and untreated mice. GFP fluorescent 
areas were recorded every 2 weeks for 12 weeks using the iBOX. 
c) Time-course imaging of the GFP-expressing bone tumors in 
S. typhimurium A1-R therapy treated mice and untreated mice. 
d) Fluorescence area of bone tumors in untreated control and S. 
typhimurium treated mice. Data are expressed as the mean ± SE. 
Differences between groups were analyzed with the Student’s 
t-test. **p < 0.01 compared with the untreated control group.
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Fluorescence imaging demonstrated that the control mice 
had rapid tumor growth of the tibial tumor. In contrast, 
the S. typhimurium A1-R-treated mice had slow growth 
(Fig. 5c). The fluorescent tumors area of the untreated 
control mice and S. typhimurium A1-R-treated mice 10 
weeks after bacterial therapy was 196.6 ± 22.1 mm2 and 
61.8 ± 15.0 mm2, respectively (P < 0.001) (Fig. 5d). The 
bone marrow was observed with an FV1000 confocal 
microscope to confirm the presence of GFP-expressing 
cancer cells.
The present study demonstrates that S. typhimuium 
A1-R has and could significantly inhibit or prevent bone 
metastasis. These results indicate a promising approach to 
a currently highly treatment-resistant disease. 
MATERIALS AND METHODS
Cell culture
MDA-MB-435-GFP cells and MDA-MB-435-RFP 
cells were generated as previously described [20-25]. 
Cells were maintained in Dulbecco’s modified Eagle’s 
medium high glucose supplemented with 10% FBS + 200 
μg/mL G418 (Gibco). Cells were subcultured for at least 
3 passages before harvesting at their linear growth phase 
(approximately 70-80% confluent) for cardiac injection of 
2×105 cells. 
Preparation of S. typhimurium A1-R
GFP-expressing Salmonella typhimurium A1-R 
bacteria (AntiCancer Inc., San Diego, CA, USA) were 
grown overnight on LB medium (Fisher Sci., Hanover 
Park, IL, USA) and then diluted 1:10 in LB medium. 
Bacteria were harvested at late-log phase, washed with 
PBS, and then diluted in PBS [4, 5].
S. typhimurium A1-R killing of breast cancer cells 
in vitro
MDA-MB-435-GFP or MDA-MB-435-RFP cells 
were planted in 35 mm dishes (2×103). S. typhimurium 
A1-R-GFP was grown in LB medium and added to 
the cancer cells (1×108 or 1×109 CFU/dish). After 1 h 
incubation at 37°C, the cells were rinsed and cultured in 
medium containing gentamycin sulfate (100 µg/ml) to kill 
external but not internal bacteria. Invasion and destruction 
of MDA-MB-435-RFP cells by S. typhimurium A1-R-GFP 
was visualized with the FV1000 confocal microscope. 
Eight days after treatment with S. typhimurium A1-R, 
MDA-MB-435-GFP colonies were fixed in methanol and 
stained with 1% crystal violet as previously described [26]. 
ImageJ (National Institute of Mental Health, Bethesda, 
Maryland, USA) was used to quantify the colonies of the 
cells. 
Distribution of S. typhimurium A1-R in blood, 
spleen, and bone marrow tissue
Tumor-free nude mice were injected with S. 
typhimurium A1-R (5×107 CFU, i.v.). On days 1, 2, 3, 
7, 14, and 28 after S. typhimurium A1-R GFP injection, 
femurs were taken from 3 mice and irrigated with PBS. 
Spleens were minced and mixed with PBS, as was 
blood. The PBS, including S. typhimurium A1-R from 
each tissue, was plated on LB agar containing 50 µg/mL 
ampicillin to identify S. typhimurium A1-R in each tissue. 
Fluorescent S. typhimurium A1-R colonies were observed 
with the OV100 Small Animal Imaging System (Olympus 
Corp., Tokyo, Japan). 
In vivo cycle selection of highly metastatic breast 
cancer cells
MDA-MB-435-GFP cells were harvested from 
subconfluent cell culture plates, washed with PBS, and 
resuspended in PBS. Cells (2×105) were injected into 
the left cardiac ventricle of female nude mice using a 
27G needle. Mice were anesthetized with a ketamine 
mixture (10 µl ketamine, HCL, 7,6 µl xylazine, 2.4 µl 
acepromazine maleate and 10 µl H2O) before injection. 
A successful injection was characterized by the pumping 
of arterial blood into the syringe. Development of bone 
metastases was initially monitored with an Illumatool 
imaging system (Lightools Research, Encinitas, CA, 
USA). To isolate cancer cells from the bone metastasis, 
mice were sacrificed, and the affected bones were excised. 
Both ends of the bones were cut open. A one ml syringe 
with a 27G needle was filled with PBS and inserted into 
one end of the bone. Mouse bone marrow cells as well 
as cancer cells were forced out from the other end by 
applying pressure to the syringe. Cells were collected 
by centrifugation and washed once with PBS before 
being cultured at 37°C. After two weeks of culture, a 
pure population of human cancer cells was obtained as 
confirmed by fluorescence imaging. After 4 cycles of this 
procedure, we obtained a highly metastatic cells line, 
termed MDA-MB-435-GFP-BM4. Time-course imaging 
of the mice after cardiac injection of MDA-MB-435-GFP-
BM4 demonstrated progression of multiple metastases to 
bone including skull, femur, and vertebrae. 
Efficacy of S. typhimurium A1-R therapy on 
early-stage experimental bone metastasis
MDA-MB-435-GFP-BM4 cells (2×105) were 
injected intracardially in nude mice. One week after 
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injection, mice (n=5) (treatment group) were administered 
S. typhimurium A1-R (5×107 CFU, i.v.) once a week 
for 3 weeks. The remaining mice (control group) were 
administered the same volume of PBS. To evaluate 
metastasis-free survival, GFP-expressing lesions were 
initially observed using the Illumatool every week. 
Metastatic bone lesions were also imaged every two weeks 
using the iBOX Scientia Imaging System (UVP LLC, 
Upland, CA, USA). Metastasis-free survival was defined 
as the time from cardiac injection of cancer cells to the 
time of detection of bone metastases with the Illumatool. 
At the end of the follow-up, the metastases were excised 
and the bone marrow was washed with PBS to confirm the 
presence of GFP-expressing cancer cells.
Efficacy of S. typhimurium therapy on breast 
cancer cell growth in the tibia
A midline skin incision (5 mm) was made just 
below the knee joint to expose the tibial tuberosity (Fig. 
6). Matrigel (5 µL) (BD Bioscience, San Jose, CA) and 
MDA-MB-435-GFP-BM4 cells (5×105) were co-injected 
into the intramedullary cavity of the tibia with a 0.5 mL 
28 G latex-free insulin syringe (0.5 mL 28 G) (TYCO 
Health Group LP, Mansfield, MA). The skin was closed 
with a 6-0 suture. Two weeks after injection, fluorescence 
imaging was performed to confirm the GFP-expressing 
tumor was growing, using the iBOX. Nude mice (n=5) 
were administered S. typhimurium A1-R (5×107 CFU, i.v.) 
once a week for 3 weeks. The remaining mice (untreated 
control group) were administered the same volume of 
PBS. Fluorescence imaging was performed on treated and 
untreated mice, and GFP-expressing areas were recorded 
every 2 weeks for 12 weeks using the iBOX.
Statistical analysis
Data showing comparisons between two groups 
were assessed using the Student’s t-test. Comparisons 
among more than two groups were assessed using analysis 
of variance (ANOVA). The Kaplan-Meier method was 
used for bone metastasis-free survival and log-rank test 
was used for statistical significance of the difference 
between the two groups. Differences were considered 
significant when p < 0.05. Data are expressed as mean 
± SEM. Statistical analyses were performed with EZR 
(Saitama Medical Center, Jichi Medical University). 
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